Evidence Level
Alpha-GPC is supported by moderate clinical evidence for its role in cognitive enhancement and athletic performance. De Jesus Moreno (2003) conducted a multicenter, double-blind, randomized, placebo-controlled trial involving 261 patients with mild to moderate Alzheimer's disease, demonstrating significant cognitive improvements after 180 days of treatment at 1200 mg/day. Ziegenfuss et al. (2008) established its ergogenic potential in a study showing a 14% increase in peak force production during resistance exercise following acute supplementation. Additionally, Kawamura et al. (2012) found that a single 1000 mg dose of α-Glycerophosphocholine increased growth hormone secretion and fat oxidation in healthy males compared to placebo.
As a choline source, Alpha-GPC delivers approximately 40% choline by weight, making it highly efficient for raising brain acetylcholine levels. Recent studies further support its cognitive benefits: Yamashita et al. (2023) reported that daily intake of 300 mg egg yolk choline improved verbal memory in middle-aged and older adults in a randomized double-blind placebo-controlled study of 41 participants. These findings collectively highlight Alpha-GPC's potential for both cognitive and athletic applications, supported by robust clinical evidence.